DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Leukeran (Chlorambucil) - Ear Infection - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Ear Infection (2)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Leukeran (Chlorambucil) where reactions include ear infection. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Leukeran side effects in 61 year old female

Reported by a individual with unspecified qualification from Ukraine on 2012-05-14

Patient: 61 year old female

Reactions: Ear Infection, Respiratory Tract Infection Viral

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rituxan
    Dosage: (375 mg/m2) intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-10-27

Leukeran
    Dosage: (18 mg/m2) intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-10-27

Ofatummab (Ofatummab)
    Dosage: intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-12-21



Possible Leukeran side effects in 61 year old female

Reported by a health professional (non-physician/pharmacist) from Ukraine on 2012-05-03

Patient: 61 year old female, weighing 74.0 kg (162.8 pounds)

Reactions: Ear Infection, Respiratory Tract Infection Viral

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ofatumumab (Ofatumumab)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-12-21

Leukeran
    Dosage: (18 mg/m2)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-10-27

Rituxan
    Dosage: (375 mg/m2)
    Indication: Chronic Lymphocytic Leukaemia Refractory
    Start date: 2011-10-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017